Bayesian pharmacokinetics of cefuroxime in critically ill septic children;Farmacocinética Bayesiana de cefuroxima en niños infectados gravemente enfermos

Revista de Investigacion Clinica

Volumn 50, Issue 4, 1998, Pages 311-316

  Lares Asseff, Ismael ^a,b,d   Lugo Goytía, Gustavo ^c   Pérez Guillé, María Gabriela ^a   Flores Pérez, Janett ^a   Juárez Olguín, Hugo ^a,b   Moreno, Ma De Los Angeles Raquel ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d Unidad de Investigación en Inmunodeficiencias   (Mexico)

Author keywords

Bayesian estimation; Cefuroxime; Critically ill; Pediatric; Pharmacokinetics; Septic

Indexed keywords

CEFUROXIME; CEPHALOSPORIN DERIVATIVE;

ADOLESCENT; ARTICLE; BAYES THEOREM; CHILD; CRITICAL ILLNESS; HUMAN; INFANT; METABOLISM; PRESCHOOL CHILD; REGRESSION ANALYSIS; SEPSIS; SEPTIC SHOCK;

ADOLESCENT; BAYES THEOREM; CEFUROXIME; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; HUMANS; INFANT; REGRESSION ANALYSIS; SEPSIS; SHOCK, SEPTIC;

EID: 0032128774     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. O'Callaghan CH, Sykes RB, Thornton JE. Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother 1976; 9:511-9.
2. Richmong HH, Wotton S. Comparative study of seven cephalosporine: susceptibility to beta-lactamases and ability to penetrate to the surface layers of Escherichia coli. Antimicrob Agents Chemother 1976; 10:210-22.
3. Sirinavin S. Chiemchanya S. Visudhipan P, Loleka S. Cefuroxime treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1984; 25:273-5.
4. Marik PE, Havlik Y, Monteagudo FSE, Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice daily dosing regimens. J Antimicrob Chemother 1991; 27(suppl C):81-9.
5. Zaske DE, Cipolle RJ, Strate RG. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980; 87:164-9.
6. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16:327-30.
7. Burton ME, Brater C, Chen SP, Day BR, Huber JP, Vasko RM. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacokinet 1985; 37:349-57.
8. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer aided drug dosage. Comput Biomed Res 1972; 5:441-59.
9. Denaro C, Revenscroft P. Comparision of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients. Br J Clin Pharmacol 1989; 28:37-44.
10. Wilson JT, Kearns GL, Murphy D, Yaffe JS. Paediatric labelling requirements: implications for pharmacokinetic studies. Clin Pharmacokinet 1994; 26:308-25.
11. Collart L, Blaschke TF, Boucher F, Prober CG. Potential of populations pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992; 18:71-80.
12. Bone RC, Fisher CJ, Clemmer TP, Slotam GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17:389-93.
13. Nilsson-Ehle, I. High pressure liquid chromatography as a tool for determination of antibiotics in biological fluids. Acta Pathol Microbiol Scand 1977; 259:61-6.
14. Jelliffe RW. Schumitzky A, Van Guilder M. User manual for the non-parametric EM program for population pharmacokinetic modeling, version 3.0. Los Angeles: University of Southern California School of Medicine 1995.
15. Jelliffe WR, Schumitzky A, Van Guilder M, Jiang F. USC*PACK collection of PC programs. Los Angeles: University of Southern California School of Medicine, 1995.
16. D'Argenio DZ, Schumitzky A. ADAPTII: mathematical software for pharmacokinetic/pharmacodynamic systems analysis. Los Angeles: University of Southern California; 1992.
17. Sheiner L, Stuart B. Scientific commentary: some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-12.
18. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22:447-67.
19. Pryka RD, Rodvold KA, Erdman SM. An update comparision of drug dosing methods (Pt1): phenytoin. Clin Pharmacokinet 1991; 20:209-17.
20. Fernández de Gatta MM, García JM, Lanao JM, Dominguez-Gil A. Bayesian forecasting in paediatric populations. Clin Pharmacokinet 1996; 31:325-30.
21. Mc Clellan SD, Farringer JA. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as internal estimates. Ther Drug Monit 1989; 11:431-6.
22. Gill MA, Okamoto MP, Nakahiro RK, Chin A, Inagaki K, Sclar DA. Pharmacokinetic population parameters of aminoglycosides in cholecystitis patients. Ther Drug Monit 1992; 14:107-11.
23. Lugo G, Castañeda-Hernandez G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997; 19:271-6.
24. Moore R, Smith C, Liethman P. Association of aminoglycoside plasma levels with therapeutic outcome in Gram negative pneumonia. Am J Med 1984; 77:652-7.
25. Smith BR, Le Frock JL. Cefuroxime: antimicrobial activity, pharmacology and clinical efficacy. Ther Drug Monit 1983; 5:149-60.
26. Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ, Altered aminoglycoside pharmacokinetics in the critically ill patient. Anaesth Intensive Care 1988; 16:418-22.
27. Van Dolan R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients, Intensive Care Med 1990; 16(suppl 3):S235-8.
28. Marik PE. Aminoglycoside volume distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21:172-3.
29. Zhanel GG, Craig AW. Pharmacokinetic contributions to postantibiotic effects. Clin Pharmacokinet 1994; 27:377-92.
30. Bréant V. Charpiat B, Sab J.M., Maire P, Jelliffe R.W. How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to ciclosporine. Eur J Clin Pharmacol 1996; 51:283-8.
31. Vozeh S, Steimer JL. Feedback control methods for drug dosage optimization. Clin Pharmacokinet 1985; 10:457-76.